Replies to post #16739 on ScripsAmerica Inc. (SCRCQ)

[martin33]

Going forward is what counts. Wait until the results for
2014 are compared to 2013. They will be MIND BOGGLING.

[coolerheadsprevail]

Agree. Revenues showed a massive decrease. Expenses increased. Had to write off $1.1M in accounts receivable. Paid $1.5M in interest expense, which is almost 3X their 2013 revenues.

No doubt that the financial results left shareholders waiting for a follow-up filing that says "April Fool's, now here are the REAL numbers!", but in reality a poor 10K (from a revenues/earnings perspective, anyways) was expected by everyone, whether retail investor or the big boys up on the Street.

What we need to see from BOTH the 10K and the 1st Qtr Q when they are filed are:

(1)
Details on how SCRC came into possession of so much cash since it stopped issuing new notes in OCT-2013. The Street has made it clear that it wants proof that there is no further dilution WHATSOEVER and that all this grandstanding re: paydowns of notes is not simply a a shell-game or bait-and-switch that SCRC is playing by merely exchanging one form of dilution (i.e. note issuances) with another (restricted stock issuances).

(2)
Hard numbers/amounts of both top-line revenues from new sources (i.e. compounding pharmacy) as well as earnings contributions from these new sources (i.e. how much new expenses were incurreed as part of generating these new revenues).

(3)
Whether $200k from initial Hong Kong RapiMeds order has been recognized yet and/or received either in part or in whole -- along with hopefully data re: margin contribution of said HK order.

(4)
Status of additional HK orders; status of RapiMeds approval in mainland China; status of PIMP; status of new DEA Class II license; etc...